Shojaee Seyedmehdi, Chan Lai N, Buchner Maike, Cazzaniga Valeria, Cosgun Kadriye Nehir, Geng Huimin, Qiu Yi Hua, von Minden Marcus Dühren, Ernst Thomas, Hochhaus Andreas, Cazzaniga Giovanni, Melnick Ari, Kornblau Steven M, Graeber Thomas G, Wu Hong, Jumaa Hassan, Müschen Markus
Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA.
Centro Ricerca Tettamanti, Clinica Pediatrica, Università di Milano-Bicocca, Monza, Italy.
Nat Med. 2016 Apr;22(4):379-87. doi: 10.1038/nm.4062. Epub 2016 Mar 14.
Phosphatase and tensin homolog (PTEN) is a negative regulator of the phosphatidylinositol 3-kinase (PI3K) and protein kinase B (AKT) signaling pathway and a potent tumor suppressor in many types of cancer. To test a tumor suppressive role for PTEN in pre-B acute lymphoblastic leukemia (ALL), we induced Cre-mediated deletion of Pten in mouse models of pre-B ALL. In contrast to its role as a tumor suppressor in other cancers, loss of one or both alleles of Pten caused rapid cell death of pre-B ALL cells and was sufficient to clear transplant recipient mice of leukemia. Small-molecule inhibition of PTEN in human pre-B ALL cells resulted in hyperactivation of AKT, activation of the p53 tumor suppressor cell cycle checkpoint and cell death. Loss of PTEN function in pre-B ALL cells was functionally equivalent to acute activation of autoreactive pre-B cell receptor signaling, which engaged a deletional checkpoint for the removal of autoreactive B cells. We propose that targeted inhibition of PTEN and hyperactivation of AKT triggers a checkpoint for the elimination of autoreactive B cells and represents a new strategy to overcome drug resistance in human ALL.
磷酸酶和张力蛋白同源物(PTEN)是磷脂酰肌醇3激酶(PI3K)和蛋白激酶B(AKT)信号通路的负调节因子,也是多种癌症中一种强大的肿瘤抑制因子。为了测试PTEN在B系前体急性淋巴细胞白血病(ALL)中的肿瘤抑制作用,我们在B系前体ALL小鼠模型中诱导了Cre介导的Pten缺失。与它在其他癌症中作为肿瘤抑制因子的作用相反,Pten一个或两个等位基因的缺失导致B系前体ALL细胞迅速死亡,并且足以清除白血病移植受体小鼠体内的白血病细胞。在人B系前体ALL细胞中对PTEN进行小分子抑制导致AKT过度激活、p53肿瘤抑制细胞周期检查点激活以及细胞死亡。B系前体ALL细胞中PTEN功能的丧失在功能上等同于自身反应性B系前体细胞受体信号的急性激活,这启动了一个用于清除自身反应性B细胞的缺失检查点。我们提出,靶向抑制PTEN和AKT的过度激活会触发一个清除自身反应性B细胞的检查点,这代表了一种克服人类ALL耐药性的新策略。